Trials / Unknown
UnknownNCT02452307
Peptide-specific Vaccination in HLA-A*02 Positive Patients With Biochemical Recurrence After Radical Prostatectomy
Prospective Randomized Trial of Peptide-specific Vaccination in HLA-A*02 Positive Prostate Carcinoma Patients With Biochemical Recurrence After Radical Prostatectomy
- Status
- Unknown
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 36 (actual)
- Sponsor
- University Hospital Tuebingen · Academic / Other
- Sex
- Male
- Age
- 45 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The study evaluates the prostate-specific antigen (PSA) response in HLA-A\*02 positive patients with biochemical recurrence after radical prostatectomy treated with a prostate-specific peptide vaccine in combination with different immune-adjuvants.
Detailed description
Patients with a biochemical recurrence after initial therapy can be included.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Peptide vaccine | subcutaneous |
| DRUG | Montanide ISA-51 | subcutaneous |
| DRUG | Granulocyte macrophage colony stimulating factor (GM-CSF) | intradermal |
| DRUG | Imiquimod | epicutaneous |
| DRUG | mRNA | subcutaneous |
| DRUG | Protamin | subcutaneous |
| PROCEDURE | local hyperthermia |
Timeline
- Start date
- 2004-04-01
- Primary completion
- 2017-10-01
- Completion
- 2017-10-01
- First posted
- 2015-05-22
- Last updated
- 2017-08-17
Source: ClinicalTrials.gov record NCT02452307. Inclusion in this directory is not an endorsement.